WO2021136463A1 - 嘌呤衍生物及其在医药上的用途 - Google Patents
嘌呤衍生物及其在医药上的用途 Download PDFInfo
- Publication number
- WO2021136463A1 WO2021136463A1 PCT/CN2020/141862 CN2020141862W WO2021136463A1 WO 2021136463 A1 WO2021136463 A1 WO 2021136463A1 CN 2020141862 W CN2020141862 W CN 2020141862W WO 2021136463 A1 WO2021136463 A1 WO 2021136463A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- heterocycloalkyl
- methyl
- halogen
- Prior art date
Links
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 240
- 239000000651 prodrug Substances 0.000 claims abstract description 23
- 229940002612 prodrug Drugs 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 125000001424 substituent group Chemical group 0.000 claims abstract description 22
- 239000012453 solvate Substances 0.000 claims abstract description 19
- 239000002207 metabolite Substances 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 110
- -1 cyano, carboxyl Chemical group 0.000 claims description 95
- 125000000623 heterocyclic group Chemical group 0.000 claims description 53
- 229910052736 halogen Inorganic materials 0.000 claims description 44
- 150000002367 halogens Chemical class 0.000 claims description 44
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 229910052799 carbon Inorganic materials 0.000 claims description 42
- 229910052757 nitrogen Inorganic materials 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 40
- 229910052760 oxygen Inorganic materials 0.000 claims description 38
- 229910052717 sulfur Inorganic materials 0.000 claims description 35
- 125000005842 heteroatom Chemical group 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 239000013078 crystal Substances 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000002009 alkene group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 150000001335 aliphatic alkanes Chemical group 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 28
- 229940126289 DNA-PK inhibitor Drugs 0.000 abstract description 4
- 230000005496 eutectics Effects 0.000 abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 154
- 238000006243 chemical reaction Methods 0.000 description 150
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 138
- 239000007787 solid Substances 0.000 description 133
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 117
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 80
- 239000000243 solution Substances 0.000 description 80
- 238000005481 NMR spectroscopy Methods 0.000 description 71
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 64
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 238000004809 thin layer chromatography Methods 0.000 description 47
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 43
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 42
- 238000010898 silica gel chromatography Methods 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 34
- 229910000024 caesium carbonate Inorganic materials 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 28
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 28
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 27
- 238000004128 high performance liquid chromatography Methods 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- 239000003208 petroleum Substances 0.000 description 19
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 17
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 17
- 229940098779 methanesulfonic acid Drugs 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 239000012043 crude product Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 12
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 12
- 239000005457 ice water Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 230000005782 double-strand break Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 10
- DTDHSUCDEYSPDW-UHFFFAOYSA-N 2-chloro-7-methyl-9-(4-oxo-1-adamantyl)purin-8-one Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3C(C(CC(C1)C3)C2)=O)=O)C DTDHSUCDEYSPDW-UHFFFAOYSA-N 0.000 description 9
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 9
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- XDEUKVGDEOEIBL-UHFFFAOYSA-N 2-chloro-9-(5-hydroxy-2-adamantyl)-7-methylpurin-8-one Chemical compound ClC1=NC=C2N(C(N(C2=N1)C1C2CC3CC(CC1C3)(C2)O)=O)C XDEUKVGDEOEIBL-UHFFFAOYSA-N 0.000 description 7
- WZXOPYZEKOOCBH-UHFFFAOYSA-N 6-methyl-2,3-dihydro-1-benzofuran-5-amine Chemical compound C1=C(N)C(C)=CC2=C1CCO2 WZXOPYZEKOOCBH-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 6
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 6
- ATVSKLCRNYLZKT-UHFFFAOYSA-N 2-chloro-4-[(3-hydroxy-1-adamantyl)amino]pyrimidine-5-carboxylic acid Chemical compound ClC1=NC=C(C(=N1)NC12CC3(CC(CC(C1)C3)C2)O)C(=O)O ATVSKLCRNYLZKT-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 239000004305 biphenyl Substances 0.000 description 6
- 235000010290 biphenyl Nutrition 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 5
- ODBNPBIYGDVQPN-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)-4-methylbenzene Chemical compound BrC1=C(C=C(C=C1)C)OCCBr ODBNPBIYGDVQPN-UHFFFAOYSA-N 0.000 description 5
- JQIOMMPGTMXBDW-UHFFFAOYSA-N 2-chloro-4-[[5-[(2-methylpropan-2-yl)oxycarbonyl]-2-adamantyl]amino]pyrimidine-5-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)C12CC3C(C(CC(C1)C3)C2)NC1=NC(=NC=C1C(=O)O)Cl JQIOMMPGTMXBDW-UHFFFAOYSA-N 0.000 description 5
- ZDMYDQJUYWLUKH-UHFFFAOYSA-N 2-chloro-9-(3-hydroxy-1-adamantyl)-7-methylpurin-8-one Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)O)=O)C ZDMYDQJUYWLUKH-UHFFFAOYSA-N 0.000 description 5
- GEZXQZJQIGKDGM-UHFFFAOYSA-N 3-(2-chloro-7-methyl-8-oxopurin-9-yl)adamantane-1-carboxamide Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)C(=O)N)=O)C GEZXQZJQIGKDGM-UHFFFAOYSA-N 0.000 description 5
- RDBZIOUVVBINOE-UHFFFAOYSA-N 3-(2-chloro-7-methyl-8-oxopurin-9-yl)adamantane-1-carboxylic acid Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)C(=O)O)=O)C RDBZIOUVVBINOE-UHFFFAOYSA-N 0.000 description 5
- PFMSVURSQDZSLD-UHFFFAOYSA-N 3-(2-chloro-8-oxo-7H-purin-9-yl)adamantane-1-carbonitrile Chemical compound ClC1=NC=C2NC(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)C#N)=O PFMSVURSQDZSLD-UHFFFAOYSA-N 0.000 description 5
- RASZUAGXPYAYPK-UHFFFAOYSA-N 3-(2-chloro-8-oxo-7H-purin-9-yl)adamantane-1-carboxamide Chemical compound ClC1=NC=C2NC(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)C(=O)N)=O RASZUAGXPYAYPK-UHFFFAOYSA-N 0.000 description 5
- SRIPASIRGVVLHD-UHFFFAOYSA-N 3-(2-chloro-8-oxo-7H-purin-9-yl)adamantane-1-carboxylic acid Chemical compound ClC1=NC=C2NC(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)C(=O)O)=O SRIPASIRGVVLHD-UHFFFAOYSA-N 0.000 description 5
- FVTNBEQDTWECHJ-UHFFFAOYSA-N 6-chloro-2,3-dihydro-1-benzofuran Chemical compound ClC1=CC=C2CCOC2=C1 FVTNBEQDTWECHJ-UHFFFAOYSA-N 0.000 description 5
- ZITRKKKFQZQRRA-UHFFFAOYSA-N 6-chloro-2,3-dihydro-1-benzofuran-5-amine Chemical compound C1=C(Cl)C(N)=CC2=C1OCC2 ZITRKKKFQZQRRA-UHFFFAOYSA-N 0.000 description 5
- ROXWPNWNRFWFEI-UHFFFAOYSA-N 6-chloro-5-nitro-2,3-dihydro-1-benzofuran Chemical compound [O-][N+](=O)c1cc2CCOc2cc1Cl ROXWPNWNRFWFEI-UHFFFAOYSA-N 0.000 description 5
- XVUOLHQHLMXCCX-UHFFFAOYSA-N 6-methyl-2,3-dihydro-1-benzofuran Chemical compound CC1=CC=C2CCOC2=C1 XVUOLHQHLMXCCX-UHFFFAOYSA-N 0.000 description 5
- IGKDOJNYCDGKOZ-UHFFFAOYSA-N 7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-amine Chemical compound CC1=CC2=NC=NN2C=C1N IGKDOJNYCDGKOZ-UHFFFAOYSA-N 0.000 description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 5
- ZHIVPNRJQSLVBP-UHFFFAOYSA-N CC1=CC2=C(CCO2)C=C1[N+](=O)[O-] Chemical compound CC1=CC2=C(CCO2)C=C1[N+](=O)[O-] ZHIVPNRJQSLVBP-UHFFFAOYSA-N 0.000 description 5
- 230000033616 DNA repair Effects 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 5
- FQFZASRJFRAEIH-UHFFFAOYSA-N adamantane-1-carbonitrile Chemical compound C1C(C2)CC3CC2CC1(C#N)C3 FQFZASRJFRAEIH-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- AQFMQBDEXRLVNQ-UHFFFAOYSA-N ethyl 2-chloro-4-[[5-[(2-methylpropan-2-yl)oxycarbonyl]-2-adamantyl]amino]pyrimidine-5-carboxylate Chemical compound C(C)(C)(C)OC(=O)C12CC3C(C(CC(C1)C3)C2)NC1=NC(=NC=C1C(=O)OCC)Cl AQFMQBDEXRLVNQ-UHFFFAOYSA-N 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- IQJFXWFZPQVOFQ-UHFFFAOYSA-N tert-butyl 3-aminoadamantane-1-carboxylate Chemical compound C1C(C2)CC3CC2(N)CC1(C(=O)OC(C)(C)C)C3 IQJFXWFZPQVOFQ-UHFFFAOYSA-N 0.000 description 5
- HLLWIXHSUIZEEI-UHFFFAOYSA-N tert-butyl 4-(2-chloro-8-oxo-7H-purin-9-yl)adamantane-1-carboxylate Chemical compound ClC1=NC=C2NC(N(C2=N1)C1C2CC3(CC(CC1C3)C2)C(=O)OC(C)(C)C)=O HLLWIXHSUIZEEI-UHFFFAOYSA-N 0.000 description 5
- BIKHERARRCXCML-UHFFFAOYSA-N tert-butyl 4-aminoadamantane-1-carboxylate Chemical compound CC(C)(C)OC(=O)C12CC3CC(C1)C(N)C(C3)C2 BIKHERARRCXCML-UHFFFAOYSA-N 0.000 description 5
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 4
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 4
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 4
- ONWZXIPJHRFSOR-UHFFFAOYSA-N 2-chloro-4-[[3-[(2-methylpropan-2-yl)oxycarbonyl]-1-adamantyl]amino]pyrimidine-5-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)C12CC3(CC(CC(C1)C3)C2)NC1=NC(=NC=C1C(=O)O)Cl ONWZXIPJHRFSOR-UHFFFAOYSA-N 0.000 description 4
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 4
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 4
- GSTOQOGJUKMGPG-UHFFFAOYSA-N 4-[[9-(5-hydroxy-2-adamantyl)-7-methyl-8-oxopurin-2-yl]amino]-3-methylbenzonitrile Chemical compound OC12CC3C(C(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC1=C(C=C(C#N)C=C1)C GSTOQOGJUKMGPG-UHFFFAOYSA-N 0.000 description 4
- LUNNHYMBXZPWBL-UHFFFAOYSA-N 9-(3-hydroxy-1-adamantyl)-7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]purin-8-one Chemical compound OC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C LUNNHYMBXZPWBL-UHFFFAOYSA-N 0.000 description 4
- OXYLQJOHAIRRDV-UHFFFAOYSA-N CCOC(C(C(NC(CC(C1)C2)(CC1C1)CC21C(OC(C)(C)C)=O)=N1)=CN=C1Cl)=O Chemical compound CCOC(C(C(NC(CC(C1)C2)(CC1C1)CC21C(OC(C)(C)C)=O)=N1)=CN=C1Cl)=O OXYLQJOHAIRRDV-UHFFFAOYSA-N 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- LUNNHYMBXZPWBL-BMSJAHLVSA-N OC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C([2H])([2H])[2H])NC=1C(=CC=2N(C=1)N=CN=2)C Chemical compound OC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C([2H])([2H])[2H])NC=1C(=CC=2N(C=1)N=CN=2)C LUNNHYMBXZPWBL-BMSJAHLVSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 4
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125846 compound 25 Drugs 0.000 description 4
- 229940125807 compound 37 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000006780 non-homologous end joining Effects 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- MNIPVWXWSPXERA-IDNZQHFXSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecanoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)CCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 MNIPVWXWSPXERA-IDNZQHFXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- PFOQIHIIOLBCEQ-UHFFFAOYSA-N 2-[4-[2-(2,6-dimethoxyphenyl)-7-methyl-3h-benzimidazol-5-yl]piperidin-1-yl]-n-methylethanamine Chemical compound C1CN(CCNC)CCC1C1=CC(C)=C(NC(=N2)C=3C(=CC=CC=3OC)OC)C2=C1 PFOQIHIIOLBCEQ-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- NSIHAMJFTYYGOI-UHFFFAOYSA-N 2-chloro-4-[(5-hydroxy-2-adamantyl)amino]pyrimidine-5-carboxylic acid Chemical compound ClC1=NC=C(C(=N1)NC1C2CC3CC(CC1C3)(C2)O)C(=O)O NSIHAMJFTYYGOI-UHFFFAOYSA-N 0.000 description 3
- XEMFCLDFBPEETD-UHFFFAOYSA-N 2-chloro-9-(5-hydroxy-2-adamantyl)-7H-purin-8-one Chemical compound ClC1=NC=C2NC(N(C2=N1)C1C2CC3CC(CC1C3)(C2)O)=O XEMFCLDFBPEETD-UHFFFAOYSA-N 0.000 description 3
- UUUAHHJMLZCPBQ-UHFFFAOYSA-N 3-(2-chloro-7-methyl-8-oxopurin-9-yl)adamantane-1-carbonitrile Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)C#N)=O)C UUUAHHJMLZCPBQ-UHFFFAOYSA-N 0.000 description 3
- VCPKJMSVPCWFDW-UHFFFAOYSA-N 3-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carbonitrile Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3(CC(CC(C1)C3)C2)C#N)=O VCPKJMSVPCWFDW-UHFFFAOYSA-N 0.000 description 3
- PPOLOAZGUUWBKL-UHFFFAOYSA-N 3-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxamide Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3(CC(CC(C1)C3)C2)C(=O)N)=O PPOLOAZGUUWBKL-UHFFFAOYSA-N 0.000 description 3
- FNKMMMVKKIGDPS-UHFFFAOYSA-N 4-[[9-(3-hydroxy-1-adamantyl)-7-methyl-8-oxopurin-2-yl]amino]-3-methylbenzamide Chemical compound OC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC1=C(C=C(C(=O)N)C=C1)C FNKMMMVKKIGDPS-UHFFFAOYSA-N 0.000 description 3
- HMPCLMSUNVOZLH-UHFFFAOYSA-N 4-aminoadamantan-1-ol Chemical compound C1C(C2)CC3C(N)C1CC2(O)C3 HMPCLMSUNVOZLH-UHFFFAOYSA-N 0.000 description 3
- CPODFPDYMIPJNP-UHFFFAOYSA-N 5-(2-chloro-7-methyl-8-oxopurin-9-yl)adamantane-2-carbonitrile Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3C(C(CC(C1)C3)C2)C#N)=O)C CPODFPDYMIPJNP-UHFFFAOYSA-N 0.000 description 3
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 3
- HOWIAIOZMUURLZ-UHFFFAOYSA-N 9-(3-hydroxy-1-adamantyl)-2-[(6-methoxy-4-methylpyridin-3-yl)amino]-7-methylpurin-8-one Chemical compound OC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C=NC(=CC=1C)OC HOWIAIOZMUURLZ-UHFFFAOYSA-N 0.000 description 3
- VEOSVZUNBDWFOP-UHFFFAOYSA-N 9-(3-hydroxy-1-adamantyl)-7-methyl-2-[(6-methyl-2,3-dihydro-1-benzofuran-5-yl)amino]purin-8-one Chemical compound OC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC2=C(CCO2)C=1)C VEOSVZUNBDWFOP-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 3
- 0 CN(c(c(N1C2(CC3C(C4)C2)CC4C3(*)O)n2)cnc2Cl)C1=O Chemical compound CN(c(c(N1C2(CC3C(C4)C2)CC4C3(*)O)n2)cnc2Cl)C1=O 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- NLLBXXHXQGZMME-UHFFFAOYSA-N ClC1=NC=C(C(=N1)NC1C2CC3CC(CC1C3)(C2)O)C(=O)OCC Chemical compound ClC1=NC=C(C(=N1)NC1C2CC3CC(CC1C3)(C2)O)C(=O)OCC NLLBXXHXQGZMME-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229940126639 Compound 33 Drugs 0.000 description 3
- 229940126650 Compound 3f Drugs 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 102100036973 X-ray repair cross-complementing protein 5 Human genes 0.000 description 3
- 101710124921 X-ray repair cross-complementing protein 5 Proteins 0.000 description 3
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 3
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 230000005865 ionizing radiation Effects 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- ZZZSDNNUFWIXBC-UHFFFAOYSA-N tert-butyl 3-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)C12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C ZZZSDNNUFWIXBC-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- NUJWKQSEJDYCDB-GNRVTEMESA-N (3s)-1-[(1s,2r,4r)-4-[methyl(propan-2-yl)amino]-2-propylcyclohexyl]-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-2-one Chemical compound CCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 NUJWKQSEJDYCDB-GNRVTEMESA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- FJZNNKJZHQFMCK-LRDDRELGSA-N 1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea Chemical compound C1(=CC(=CC(=C1[C@H]1[C@@H](C(=O)NC1)NC(=O)NC1=CC=CC=C1)F)OC)F FJZNNKJZHQFMCK-LRDDRELGSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- HCNRSSYTTGUZQW-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C(OCCBr)=C1 HCNRSSYTTGUZQW-UHFFFAOYSA-N 0.000 description 2
- XZORQADPEUSNQJ-UHFFFAOYSA-N 2-(3-piperidin-4-yloxy-1-benzothiophen-2-yl)-5-[(1,3,5-trimethylpyrazol-4-yl)methyl]-1,3,4-oxadiazole Chemical compound CC1=NN(C)C(C)=C1CC1=NN=C(C2=C(C3=CC=CC=C3S2)OC2CCNCC2)O1 XZORQADPEUSNQJ-UHFFFAOYSA-N 0.000 description 2
- CJLZUKCACMUYFP-GOSISDBHSA-N 2-[(5R)-4-[2-[3-(3-methylbutanoyloxy)phenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound CC(C)CC(=O)OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 CJLZUKCACMUYFP-GOSISDBHSA-N 0.000 description 2
- BQVJZODGBPKJMY-UHFFFAOYSA-N 2-[(6-chloro-2,3-dihydro-1-benzofuran-5-yl)amino]-9-(3-hydroxy-1-adamantyl)-7-methylpurin-8-one Chemical compound ClC1=CC2=C(CCO2)C=C1NC1=NC=C2N(C(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)O)=O)C BQVJZODGBPKJMY-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 2
- RXBRDXICTYJSJH-UHFFFAOYSA-N 2-chloro-9-(3-hydroxy-1-adamantyl)-7H-purin-8-one Chemical compound ClC1=NC=C2NC(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)O)=O RXBRDXICTYJSJH-UHFFFAOYSA-N 0.000 description 2
- GDFFAFFTIKCPDK-UHFFFAOYSA-N 2-chloro-9-(4-hydroxy-1-adamantyl)-7-methylpurin-8-one Chemical compound CN1C2=CN=C(N=C2N(C1=O)C34CC5CC(C3)C(C(C5)C4)O)Cl GDFFAFFTIKCPDK-UHFFFAOYSA-N 0.000 description 2
- XKDPTBUPZAVEOG-UHFFFAOYSA-N 2-fluoro-4-[[9-(3-hydroxy-1-adamantyl)-7-methyl-8-oxopurin-2-yl]amino]-5-methylbenzamide Chemical compound FC1=C(C(=O)N)C=C(C(=C1)NC1=NC=C2N(C(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)O)=O)C)C XKDPTBUPZAVEOG-UHFFFAOYSA-N 0.000 description 2
- MFRLROIRSRJUHZ-UHFFFAOYSA-N 2-fluoro-4-[[9-(5-hydroxy-2-adamantyl)-7-methyl-8-oxopurin-2-yl]amino]-5-methylbenzamide Chemical compound FC1=C(C(=O)N)C=C(C(=C1)NC1=NC=C2N(C(N(C2=N1)C1C2CC3CC(CC1C3)(C2)O)=O)C)C MFRLROIRSRJUHZ-UHFFFAOYSA-N 0.000 description 2
- UHPPCCNMSXULFS-UHFFFAOYSA-N 2-fluoro-5-methyl-4-[[7-methyl-8-oxo-9-(4-oxo-1-adamantyl)purin-2-yl]amino]benzamide Chemical compound FC1=C(C(=O)N)C=C(C(=C1)NC1=NC=C2N(C(N(C2=N1)C12CC3C(C(CC(C1)C3)C2)=O)=O)C)C UHPPCCNMSXULFS-UHFFFAOYSA-N 0.000 description 2
- LLVSOPNJCANJGO-UHFFFAOYSA-N 3-[2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxo-7H-purin-9-yl]adamantane-1-carbonitrile Chemical compound CC1=CC=2N(C=C1NC1=NC=C3NC(N(C3=N1)C13CC4(CC(CC(C1)C4)C3)C#N)=O)N=CN=2 LLVSOPNJCANJGO-UHFFFAOYSA-N 0.000 description 2
- MFZJAPNMIQNMDL-UHFFFAOYSA-N 3-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxylic acid Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3(CC(CC(C1)C3)C2)C(=O)O)=O MFZJAPNMIQNMDL-UHFFFAOYSA-N 0.000 description 2
- VRAOAJQFXDUZSU-UHFFFAOYSA-N 4-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carbonitrile Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C1C2CC3(CC(CC1C3)C2)C#N)=O VRAOAJQFXDUZSU-UHFFFAOYSA-N 0.000 description 2
- KCQVMFOMXSUJQQ-UHFFFAOYSA-N 4-[[9-(3-cyano-1-adamantyl)-7-methyl-8-oxopurin-2-yl]amino]-2-fluoro-5-methylbenzamide Chemical compound C(#N)C12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC1=CC(=C(C(=O)N)C=C1C)F KCQVMFOMXSUJQQ-UHFFFAOYSA-N 0.000 description 2
- VRTMBPKQKBTREU-UHFFFAOYSA-N 4-[[9-(4,4-dimethoxy-1-adamantyl)-7-methyl-8-oxopurin-2-yl]amino]-2-fluoro-5-methylbenzamide Chemical compound COC1(C2CC3(CC(CC1C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC1=CC(=C(C(=O)N)C=C1C)F)OC VRTMBPKQKBTREU-UHFFFAOYSA-N 0.000 description 2
- MSJCWVPPZANINQ-UHFFFAOYSA-N 5-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-2-carbonitrile Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3C(C(CC(C1)C3)C2)C#N)=O MSJCWVPPZANINQ-UHFFFAOYSA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- UVDYRIFUBQGAPO-UHFFFAOYSA-N 7-methyl-2-[(6-methyl-2,3-dihydro-1-benzofuran-5-yl)amino]-9-(4-oxo-1-adamantyl)purin-8-one Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC2=C(CCO2)C=1)C)C12CC3C(C(CC(C1)C3)C2)=O)=O UVDYRIFUBQGAPO-UHFFFAOYSA-N 0.000 description 2
- PLXHZHDXLUNNTD-UHFFFAOYSA-N 7-methyl-6-nitro-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC1=CC2=NC=NN2C=C1[N+]([O-])=O PLXHZHDXLUNNTD-UHFFFAOYSA-N 0.000 description 2
- RECVJAVBRBUOPE-UHFFFAOYSA-N 9-(3-hydroxy-1-adamantyl)-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-7H-purin-8-one Chemical compound OC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2NC1=O)NC=1C(=CC=2N(C=1)N=CN=2)C RECVJAVBRBUOPE-UHFFFAOYSA-N 0.000 description 2
- CWEJYEAAPGRLLR-UHFFFAOYSA-N 9-(3-methoxy-1-adamantyl)-7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]purin-8-one Chemical compound COC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C CWEJYEAAPGRLLR-UHFFFAOYSA-N 0.000 description 2
- RYEDTIANDWLHFB-UHFFFAOYSA-N 9-(4,4-dimethoxy-1-adamantyl)-7-methyl-2-[(6-methyl-2,3-dihydro-1-benzofuran-5-yl)amino]purin-8-one Chemical compound COC1(C2CC3(CC(CC1C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC2=C(CCO2)C=1)C)OC RYEDTIANDWLHFB-UHFFFAOYSA-N 0.000 description 2
- CIHKNZWRWTVRCK-UHFFFAOYSA-N 9-(4,4-dimethoxy-1-adamantyl)-7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]purin-8-one Chemical compound COC1(C2CC3(CC(CC1C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C)OC CIHKNZWRWTVRCK-UHFFFAOYSA-N 0.000 description 2
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 2
- LPWKFUVWWQYLOD-UHFFFAOYSA-N 9-(dimethylamino)-3-(4-methylphenyl)pyrido[2,3]thieno[2,4-d]pyrimidin-4-one Chemical compound C1=2C(N(C)C)=CN=CC=2SC(C2=O)=C1N=CN2C1=CC=C(C)C=C1 LPWKFUVWWQYLOD-UHFFFAOYSA-N 0.000 description 2
- WUZBOJXXYMKMMF-UHFFFAOYSA-N COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F Chemical compound COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F WUZBOJXXYMKMMF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical compound C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NVQMLNHOFAMSPZ-UHFFFAOYSA-N adamantane-1-carboxamide Chemical compound C1C(C2)CC3CC2CC1(C(=O)N)C3.C1C(C2)CC3CC2CC1(C(=O)N)C3 NVQMLNHOFAMSPZ-UHFFFAOYSA-N 0.000 description 2
- JIMXXGFJRDUSRO-UHFFFAOYSA-M adamantane-1-carboxylate Chemical compound C1C(C2)CC3CC2CC1(C(=O)[O-])C3 JIMXXGFJRDUSRO-UHFFFAOYSA-M 0.000 description 2
- KHCMWKSXPURXRL-UHFFFAOYSA-N adamantane-2-carbonitrile Chemical compound C1C(C2)CC3CC1C(C#N)C2C3 KHCMWKSXPURXRL-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125796 compound 3d Drugs 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- CJPMSUUANYLPET-UHFFFAOYSA-N n-[3-[[5-cyclopropyl-2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NCCCNC(C(=CN=1)C2CC2)=NC=1NC(C=C1)=CC=C1N1CCOCC1 CJPMSUUANYLPET-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- BGJLIQQLHUDEMT-UHFFFAOYSA-N tert-butyl 3-(2-chloro-7-methyl-8-oxopurin-9-yl)adamantane-1-carboxylate Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)C(=O)OC(C)(C)C)=O)C BGJLIQQLHUDEMT-UHFFFAOYSA-N 0.000 description 2
- OIWKVIDPEPOKCT-UHFFFAOYSA-N tert-butyl 3-(2-chloro-8-oxo-7H-purin-9-yl)adamantane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)C12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2NC1=O)Cl OIWKVIDPEPOKCT-UHFFFAOYSA-N 0.000 description 2
- VVBVAXJANYYKMJ-UHFFFAOYSA-N tert-butyl 4-(2-chloro-7-methyl-8-oxopurin-9-yl)adamantane-1-carboxylate Chemical compound ClC1=NC=C2N(C(N(C2=N1)C1C2CC3(CC(CC1C3)C2)C(=O)OC(C)(C)C)=O)C VVBVAXJANYYKMJ-UHFFFAOYSA-N 0.000 description 2
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- BFDBKMOZYNOTPK-UHFFFAOYSA-N vonoprazan Chemical compound C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F BFDBKMOZYNOTPK-UHFFFAOYSA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- WGABOZPQOOZAOI-UHFFFAOYSA-N 2-[4-[[(3,5-dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid Chemical compound COC1=C(C)C(OC)=CC(C(=O)N(CCCC=2C=CC=CC=2)CC=2C=CC(CC(O)=O)=CC=2)=C1 WGABOZPQOOZAOI-UHFFFAOYSA-N 0.000 description 1
- WWGPJMNOBVKDQO-UHFFFAOYSA-N 2-bromo-5-methylphenol Chemical compound CC1=CC=C(Br)C(O)=C1 WWGPJMNOBVKDQO-UHFFFAOYSA-N 0.000 description 1
- BMGVRFGOMBFTCG-UHFFFAOYSA-N 2-chloro-9-(3-methoxy-1-adamantyl)-7-methylpurin-8-one Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)OC)=O)C BMGVRFGOMBFTCG-UHFFFAOYSA-N 0.000 description 1
- DMMQHOUQHNWIDA-UHFFFAOYSA-N 2-chloro-9-(4-oxo-1-adamantyl)-7H-purin-8-one Chemical compound ClC1=NC=C2NC(N(C2=N1)C12CC3C(C(CC(C1)C3)C2)=O)=O DMMQHOUQHNWIDA-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- VGOALPIDEXVYQI-UHFFFAOYSA-N 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-n-[3-imidazol-1-yl-5-(trifluoromethyl)phenyl]-4-methylbenzamide Chemical compound C1=C(C#CC=2N3N=CC=CC3=NC=2)C(C)=CC=C1C(=O)NC(C=C(C=1)C(F)(F)F)=CC=1N1C=CN=C1 VGOALPIDEXVYQI-UHFFFAOYSA-N 0.000 description 1
- DWPIPTNBOVJYAD-UHFFFAOYSA-N 3-aminoadamantan-1-ol Chemical compound C1C(C2)CC3CC1(N)CC2(O)C3 DWPIPTNBOVJYAD-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 1
- KEFRHINLXUGTNO-UHFFFAOYSA-N 4-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxamide Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C1C2CC3(CC(CC1C3)C2)C(=O)N)=O KEFRHINLXUGTNO-UHFFFAOYSA-N 0.000 description 1
- OTXAIWBLLAWOMW-UHFFFAOYSA-N 4-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxylic acid Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C1C2CC3(CC(CC1C3)C2)C(=O)O)=O OTXAIWBLLAWOMW-UHFFFAOYSA-N 0.000 description 1
- XHRPMBBQOOESTF-UHFFFAOYSA-N 4-[[9-(4-cyano-1-adamantyl)-7-methyl-8-oxopurin-2-yl]amino]-2-fluoro-5-methylbenzamide Chemical compound C(#N)C1C2CC3(CC(CC1C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC1=CC(=C(C(=O)N)C=C1C)F XHRPMBBQOOESTF-UHFFFAOYSA-N 0.000 description 1
- JGJKXCZIMZZYFU-UHFFFAOYSA-N 4-amino-2-fluoro-5-methylbenzamide Chemical compound Cc1cc(C(N)=O)c(F)cc1N JGJKXCZIMZZYFU-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- BQBXTEXZQAHVCF-UHFFFAOYSA-N 5-[[9-(3-hydroxy-1-adamantyl)-7-methyl-8-oxopurin-2-yl]amino]-N,4-dimethylpyridine-2-carboxamide Chemical compound OC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC(=NC=1)C(=O)NC)C BQBXTEXZQAHVCF-UHFFFAOYSA-N 0.000 description 1
- SADFQZLBHHKCMF-UHFFFAOYSA-N 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(4-oxo-1-adamantyl)purin-8-one Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3C(C(CC(C1)C3)C2)=O)=O SADFQZLBHHKCMF-UHFFFAOYSA-N 0.000 description 1
- JEDQHFMEYOZWRP-UHFFFAOYSA-N 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-[3-(morpholine-4-carbonyl)-1-adamantyl]purin-8-one Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3(CC(CC(C1)C3)C2)C(=O)N1CCOCC1)=O JEDQHFMEYOZWRP-UHFFFAOYSA-N 0.000 description 1
- KVQRYABFFFQRHE-UHFFFAOYSA-N 7-methylquinolin-6-amine Chemical compound C1=CC=C2C=C(N)C(C)=CC2=N1 KVQRYABFFFQRHE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ULEDSOFWLJZHSB-UHFFFAOYSA-N 9-(3-amino-1-adamantyl)-7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]purin-8-one Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3(CC(CC(C1)C3)C2)N)=O ULEDSOFWLJZHSB-UHFFFAOYSA-N 0.000 description 1
- WURQLVZMEMMIDK-UHFFFAOYSA-N 9-(3-hydroxy-1-adamantyl)-7-methyl-2-[(7-methylquinolin-6-yl)amino]purin-8-one Chemical compound OC12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C=C2C=CC=NC2=CC=1C WURQLVZMEMMIDK-UHFFFAOYSA-N 0.000 description 1
- VKNLFICRXUUJJR-UHFFFAOYSA-N 9-(4-hydroxy-1-adamantyl)-7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]purin-8-one Chemical compound OC1C2CC3(CC(CC1C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C VKNLFICRXUUJJR-UHFFFAOYSA-N 0.000 description 1
- REGHCJYWNGCGDR-UHFFFAOYSA-N 9-[3-(hydroxymethyl)-1-adamantyl]-7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]purin-8-one Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3(CC(CC(C1)C3)C2)CO)=O REGHCJYWNGCGDR-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ISBJPRPDGDRVLS-QYKNYGDISA-N C12(CC3C(C(CC(C1)C3)C2)[2H])N1C2=NC(=NC=C2N(C1=O)C)NC1=CC(=C(C(=O)N)C=C1C)F Chemical compound C12(CC3C(C(CC(C1)C3)C2)[2H])N1C2=NC(=NC=C2N(C1=O)C)NC1=CC(=C(C(=O)N)C=C1C)F ISBJPRPDGDRVLS-QYKNYGDISA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- VSZVCLXPAGJDSB-UHFFFAOYSA-N CCO/C(/c(c(NC(CC(C1)C2)(CC1C1)CC21C(OC(C)(C)C)=O)n1)cnc1Cl)=[O]/[O]=C(/C(CC(C1)C2)(CC1C1)CC21N(c1nc(Nc2c[n]3ncnc3cc2C)ncc1N1C)C1=O)\OC(C)(C)C Chemical compound CCO/C(/c(c(NC(CC(C1)C2)(CC1C1)CC21C(OC(C)(C)C)=O)n1)cnc1Cl)=[O]/[O]=C(/C(CC(C1)C2)(CC1C1)CC21N(c1nc(Nc2c[n]3ncnc3cc2C)ncc1N1C)C1=O)\OC(C)(C)C VSZVCLXPAGJDSB-UHFFFAOYSA-N 0.000 description 1
- ZKAPQAMYMUOQED-IZZDOVSWSA-N CN(\C=N\C1=NC=C(C(=C1)C)[N+](=O)[O-])C Chemical compound CN(\C=N\C1=NC=C(C(=C1)C)[N+](=O)[O-])C ZKAPQAMYMUOQED-IZZDOVSWSA-N 0.000 description 1
- MFUSUYDROYROIA-UHFFFAOYSA-N CN(c(c(N1C2(CC3C(C4)C2)CC4C3C#N)n2)cnc2Cl)C1=O Chemical compound CN(c(c(N1C2(CC3C(C4)C2)CC4C3C#N)n2)cnc2Cl)C1=O MFUSUYDROYROIA-UHFFFAOYSA-N 0.000 description 1
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 1
- KHVUNGAITCZNAY-UHFFFAOYSA-N Cc(cc(C(N)=O)c(F)c1)c1Nc(nc1N2C3(CC4C(C5)C3)CC5C4(OC)OC)ncc1N(C)C2=O Chemical compound Cc(cc(C(N)=O)c(F)c1)c1Nc(nc1N2C3(CC4C(C5)C3)CC5C4(OC)OC)ncc1N(C)C2=O KHVUNGAITCZNAY-UHFFFAOYSA-N 0.000 description 1
- QNPUOVYDAUGYNG-UHFFFAOYSA-N Cc(cc(C(N)=O)c(F)c1)c1Nc(nc1N2C3(CC4C(C5)C3)CC5C4=O)ncc1N(C)C2=O Chemical compound Cc(cc(C(N)=O)c(F)c1)c1Nc(nc1N2C3(CC4C(C5)C3)CC5C4=O)ncc1N(C)C2=O QNPUOVYDAUGYNG-UHFFFAOYSA-N 0.000 description 1
- CUJSSIOATYIWKA-UHFFFAOYSA-N Cc1cc(C(N)=O)ccc1N Chemical compound Cc1cc(C(N)=O)ccc1N CUJSSIOATYIWKA-UHFFFAOYSA-N 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- GDFFAFFTIKCPDK-UQBWLURTSA-N ClC1=NC=C2N(C(N(C2=N1)C12CC3C(C(CC(C1)C3)C2)([2H])O)=O)C Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3C(C(CC(C1)C3)C2)([2H])O)=O)C GDFFAFFTIKCPDK-UQBWLURTSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 229920006061 Kelon® Polymers 0.000 description 1
- 102000015335 Ku Autoantigen Human genes 0.000 description 1
- 108010025026 Ku Autoantigen Proteins 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- ZBPOKYGSYKBAAW-UHFFFAOYSA-N NC(CC(C1)C2)(CC1C1)CC21C(O)=O Chemical compound NC(CC(C1)C2)(CC1C1)CC21C(O)=O ZBPOKYGSYKBAAW-UHFFFAOYSA-N 0.000 description 1
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 1
- VSSLXMWBLJCURN-UICOGKGYSA-N OC1C2(CC3CC(C(C1C3)[2H])C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C Chemical compound OC1C2(CC3CC(C(C1C3)[2H])C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C VSSLXMWBLJCURN-UICOGKGYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- COGNCXJCCDGTDV-UHFFFAOYSA-N [O].N1C=CC=CC=C1 Chemical compound [O].N1C=CC=CC=C1 COGNCXJCCDGTDV-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 229940125876 compound 15a Drugs 0.000 description 1
- 229940126212 compound 17a Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- IYBFDPIRLGPIHD-UHFFFAOYSA-N ethyl 2-chloro-4-[(3-hydroxy-1-adamantyl)amino]pyrimidine-5-carboxylate Chemical compound ClC1=NC=C(C(=N1)NC12CC3(CC(CC(C1)C3)C2)O)C(=O)OCC IYBFDPIRLGPIHD-UHFFFAOYSA-N 0.000 description 1
- CVYOIIFOZMJUEJ-UHFFFAOYSA-N ethyl 3-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxylate Chemical compound C(C)OC(=O)C12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C CVYOIIFOZMJUEJ-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- UOAFDSSVMZBUBX-UHFFFAOYSA-N n-hydroxy-n'-(4-methyl-5-nitropyridin-2-yl)methanimidamide Chemical compound CC1=CC(N=CNO)=NC=C1[N+]([O-])=O UOAFDSSVMZBUBX-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002262 penten-4-yl group Chemical group C=CCC(C)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- MQDVUDAZJMZQMF-UHFFFAOYSA-N pyridin-2-ylurea Chemical compound NC(=O)NC1=CC=CC=N1 MQDVUDAZJMZQMF-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003244 quercetin derivatives Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000033863 telomere maintenance Effects 0.000 description 1
- QRVVOMZZLFOLAF-UHFFFAOYSA-N tert-butyl 4-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)C12CC3C(C(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C QRVVOMZZLFOLAF-UHFFFAOYSA-N 0.000 description 1
- JYRWUSXRTGACLY-UHFFFAOYSA-N tert-butyl 4-[[3-(4-methylsulfonylphenyl)-[1,2]oxazolo[4,5-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC2=C1ON=C2C1=CC=C(S(C)(=O)=O)C=C1 JYRWUSXRTGACLY-UHFFFAOYSA-N 0.000 description 1
- LYQKUIXZBZYXKO-UHFFFAOYSA-N tert-butyl 4-oxoadamantane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)C12CC3C(C(CC(C1)C3)C2)=O LYQKUIXZBZYXKO-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 125000005065 undecenyl group Chemical group C(=CCCCCCCCCC)* 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention relates to purine derivatives represented by general formula (I), or their stereoisomers, solvates, prodrugs, metabolites, deuterated products, pharmaceutically acceptable salts or co-crystals, their pharmaceutical compositions and Preparation of DNA-PK inhibitors.
- DNA-dependent protein kinase is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). The enzyme complex needs to be activated with the participation of DNA to perform its corresponding functions (George et al., 2019). As a serine/threonine protein kinase, DNA-PK belongs to the PIKK (phosphatidylinositol 3-kinase-related kinase) family.
- PIKK phosphatidylinositol 3-kinase-related kinase
- DSBs In the normal physiological process, a variety of factors may lead to the occurrence of DSBs in DNA: For example, DSBs often appear as intermediate products in the process of somatic DNA recombination. This physiological process is very important for the formation of the functional immune system of all vertebrates; DNA replication is in progress. When the replication fork encounters damaged bases, it may also cause single-strand or double-strand breaks; DNA may also generate DSBs due to the attack of reactive oxygen species (ROS) during normal metabolism (Cannan & Pederson, 2016).
- ROS reactive oxygen species
- DSBs ionizing radiation (IR) and chemotherapeutic agents (such as topoisomerase II inhibitors)
- IR ionizing radiation
- chemotherapeutic agents such as topoisomerase II inhibitors
- NHEJ non-homologous end-joining
- NHEJ is a dynamic process mediated by DNA-PK that requires the participation of multiple proteins and signaling pathways.
- the basic process is as follows: (1) Ku70/Ku80 heterodimer recognizes and binds to the ends of double-stranded DNA breaks; (2) Recruitment DNA-PKcs, XRCC4-DNA ligase IV complex and other proteins to both sides of the DNA break double-strand; (3) DNA-PKcs autophosphorylate and activate its own kinase activity; (4) DNA-PKcs as an adhesive to connect Break both ends of the DNA to prevent exonuclease from degrading the DNA; (5) Process the DNA to remove unlinkable ends or other forms of damage at the break; (6) XRCC4-DNA ligase IV complex repair DNA ends (in some cases, DNA polymerase may be required to synthesize new ends before ligation).
- DNA-PKcs When DNA-PKcs is phosphorylated, it can induce protein conformation to change and regulate the activity of various proteins in the NHEJ process (such as Artemis, Ku70, Ku80, DNA ligase), which is essential for the DNA repair process. Therefore, phosphorylated DNA-PKcs (pDNA-PKcs) is often used as a marker of cellular DSBs.
- DNA-PK activity is related to the occurrence and development of a variety of tumors: for example, DNA-PKcs in melanoma can promote angiogenesis and tumor metastasis; DNA-PKcs expression in multiple myeloma is significantly up-regulated; radiotherapy The content of Ku protein in tolerant thyroid tumors is significantly increased (Ihara, Ashizawa, Shichijo, & Kudo, 2019). Therefore, it can be considered to combine DNA-PK inhibitors with anti-tumor therapies that cause DNA damage (such as IR, chemotherapeutic agents, etc.) to improve the effect.
- the use of DNA-PK inhibitors can interfere with the DNA repair function of normal cells to a certain extent. However, there are many DNA repair pathways in normal cells as a supplement, and tumor cells face strong DNA replication pressure and lack effective DNA repair methods. . By inhibiting the activity of tumor cell DNA-PK, the killing effect of other anti-tumor drugs on tumor cells can be improved.
- DNA-PK inhibitors After years of research, several DNA-PK inhibitors have been discovered.
- the first compound found to have DNA-PK kinase inhibitory activity is a fungal metabolite-Wortmannin, with an IC50 (DNA-PK) of about 15nM.
- DNA-PK IC50
- This compound also plays an important role in the acetylation and phosphorylation of p53 protein ( Sarkaria et al., 1998); LY294002, a quercetin derivative reported later, also has DNA-PK inhibitory activity (Maira, Stauffer, Schnell, & Garcia-Echeverria, 2009); later based on the structure of LY294002, NU7026 and NU7441 were developed.
- a generation of DNA-PK inhibitors A generation of DNA-PK inhibitors.
- DNA-PK inhibitors have also been reported, such as OK1035, SU11752, PP121, KU-0060648 and other small molecule compounds, but these compounds also have defects such as low specificity for DNA-PK (George et al., 2019). Therefore, there is still a need to develop DNA-PK inhibitors with high activity, high specificity, and low toxicity to better meet clinical needs.
- One or more embodiments of the present invention provide purine derivatives, or their stereoisomers, solvates, metabolites, deuterated substances, pharmaceutically acceptable salts, co-crystals or prodrugs, their pharmaceutical compositions and their In the preparation of DNA-PK inhibitors.
- the compound has high inhibitory activity and/or high selectivity for DNA-PK, which can overcome the shortcomings of the prior art, and can be used as a chemotherapy and radiotherapy sensitizer to effectively treat cancer and improve the existing The curative effect of the technology, while reducing toxic side effects.
- One or more embodiments of the present invention disclose the compound represented by the general formula (I), or its stereoisomers, solvates, prodrugs, metabolites, deuterated products, pharmaceutically acceptable salts or co-crystals:
- A does not exist or is selected from a 4- to 12-membered heterocyclic ring, said heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S;
- X 1 and X 2 are each independently selected from C, O
- B is selected from an adamantyl group
- R 2 is selected from H or C 1-6 alkyl
- R 3 is selected from H, halogen, C 1-6 alkyl or C 1-6 alkoxy;
- R 4 is selected from H, C 1-6 alkyl, C 3-12 cycloalkyl, C 3 heterocycloalkyl or C 4-12 heterocycloalkyl, said C 3 heterocycloalkyl or C 4- 12 Heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O or S, the C 1-6 alkyl, C 3-12 cycloalkyl, C 3 heterocycloalkyl or C 4-12
- R 3 and R 4 and the atoms to which they are connected form a 4- to 12-membered heterocyclic ring.
- the heterocyclic ring may contain 1 to 3 heteroatoms selected from N, O or S.
- R a3 is selected from C 1-6 alkyl, C 1-6 alkoxy or C 6-12 aryl;
- R a4 and R a5 are each independently selected from H or C 1-6 alkyl
- W is selected from O or S
- n, p, and q are each independently 0, 1, 2, 3, or 4;
- One or more embodiments provide a compound represented by the general formula (II) or its stereoisomers, solvates, metabolites, prodrugs, deuterated products, pharmaceutically acceptable salts or co-crystals:
- A does not exist or is selected from a 4- to 12-membered heterocyclic ring, said heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S;
- X 1 and X 2 are each independently selected from C or N, and when A is selected from a 4- to 12-membered heterocyclic ring, X 1 and X 2 are part of the A ring;
- B is selected from an adamantyl group
- n is selected from 2, 3 or 4
- two R 0 and the atoms to which it is connected can form a 3- to 8-membered ring, and the ring optionally contains 1 to 3 heteroatoms selected from N, O or S
- R 3 is selected from H, halogen, C 1-6 alkyl or C 1-6 alkoxy;
- R 4 is selected from H, C 1-6 alkyl, C 3-12 cycloalkyl, C 3 heterocycloalkyl or C 4-12 heterocycloalkyl, said C 3 heterocycloalkyl or C 4- 12 Heterocycloalkyl contains 1 to 3 heteroatoms selected from N, O or S, the C 1-6 alkyl, C 3-12 cycloalkyl, C 3 heterocycloalkyl or C 4-12
- R a3 is selected from C 1-6 alkyl, C 1-6 alkoxy or C 6-12 aryl;
- R a4 and R a5 are each independently selected from H or C 1-6 alkyl; or R a4 and R a5 and N atoms form a 3 to 12 membered heterocyclic ring, and the 3 to 12 membered heterocyclic ring includes 1 to 4 One heteroatom selected from N, O or S;
- n, p, q are each independently selected from 0, 1, 2, 3, or 4;
- One or more embodiments of the present application provide compounds represented by general formulas (III), (IV), (V), (VI), (VII) or (VIII), or their stereoisomers, solvates, metabolism Products, prodrugs, deuterated products, pharmaceutically acceptable salts or co-crystals:
- R 0 , R 1 , R 3 , R 4 , R 5 , B, n, p, and q are the same as those described in the general formula (II).
- One or more embodiments of the present application provide a compound, or its stereoisomer, solvate, metabolite, prodrug, deuterated product, pharmaceutically acceptable salt or co-crystal, wherein:
- A does not exist or is selected from a 5-membered heterocyclic ring, said heterocyclic ring containing 1 to 3 heteroatoms selected from N or O;
- X 1 and X 2 are each independently selected from C or N, and when A is selected from a 5-membered heterocyclic ring, X 1 and X 2 are part of the A ring;
- B is selected from an adamantyl group
- R 0 is selected from H
- R 3 is selected from H
- R 4 is selected from H or C 1-4 alkyl
- R a1 and R a2 are each independently selected from H or C 1-4 alkyl; or R a1 and R a2 and N atoms form a 6-membered heterocyclic ring, and the 6-membered heterocyclic ring includes 1 to 2 selected from N Or heteroatom of O;
- n is selected from 0 or 1;
- p is selected from 1, 2 or 3;
- q is selected from 1 or 2;
- One or more embodiments of the present application provide a compound, or its stereoisomer, solvate, metabolite, prodrug, deuterated product, pharmaceutically acceptable salt or co-crystal, wherein the compound is selected from but not limited to:
- the present invention also provides intermediates for preparing compounds of general formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (VIX) or (VX)
- the intermediate compound is selected from compounds represented by general formula (IA) or (IB):
- X is selected from halogen
- B is selected from an adamantyl group
- R x is selected from H or C1-6 alkyl
- R 4 , R 5 and the definitions of (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (VIX) or (VX) The definitions are the same.
- One or more embodiments of this application provide the preparation of general formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (VIX) or (VX)
- the intermediate compound of the compound of ), the intermediate compound is selected from one of the following structures:
- composition comprising:
- One or more embodiments of the application provide the pharmaceutical composition of the application or the compound or its stereoisomers, solvates, metabolites, deuterated products, pharmaceutically acceptable salts, co-crystals or prodrugs. Use in the preparation of DNA-PK inhibitor drugs.
- the DNA-PK inhibitor is used to treat cancer.
- One or more embodiments of the present application provide the compound of the present application for use as a medicine.
- One or more embodiments of the present application provide the compound of the present application for use as a DNA-PK inhibitor.
- One or more embodiments of the present application provide a compound of the present application for use in a method of treating, preventing, or inhibiting cancer.
- One or more embodiments of the present application provide a compound of the present application for use in a method of inhibiting DNA-PK.
- One or more embodiments of the present application provide a method of treating, preventing or inhibiting cancer, which comprises administering the compound of the present application to a subject in need.
- One or more embodiments of the present application provide a method for inhibiting DNA-PK, which includes administering the compound of the present application to a subject in need.
- the carbon, hydrogen, oxygen, sulfur, nitrogen or F, Cl, Br, and I involved in the groups and compounds of the present invention include their isotopes, and the carbon involved in the groups and compounds of the present invention , Hydrogen, oxygen, sulfur or nitrogen are optionally further replaced by one or more of their corresponding isotopes, wherein carbon isotopes include 12 C, 13 C and 14 C, and hydrogen isotopes include protium (H), deuterium (D, Also called heavy hydrogen), tritium (T, also called super heavy hydrogen), oxygen isotopes include 16 O, 17 O and 18 O, sulfur isotopes include 32 S, 33 S, 34 S and 36 S, and nitrogen isotopes include 14 N and 15 N, fluorine isotopes include 17 F and 19 F, chlorine isotopes include 35 Cl and 37 Cl, and bromine isotopes include 79 Br and 81 Br.
- carbon isotopes include 12 C, 13 C and 14 C
- hydrogen isotopes include
- Alkyl refers to a linear or branched saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably 1 to 8 (for example, 1, 2, 3, 4, 5, 6, 7, 8) carbon atoms
- the alkyl group of is more preferably an alkyl group of 1 to 6 carbon atoms, and still more preferably an alkyl group of 1 to 4 carbon atoms.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl And its various branched isomers; when the alkyl group is substituted, it may be optionally further substituted with one or more substituents.
- Alkoxy refers to a group formed by replacing at least one carbon atom in an alkyl group with an oxygen atom.
- Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropyl Oxy and cyclobutoxy.
- the definition of the alkyl group is the same as the definition of "alkyl" mentioned above.
- Alkenyl refers to a straight line consisting of 1 to 10 (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) carbon-carbon double bonds consisting of 2 to 20 carbon atoms. Chain or branched unsaturated aliphatic hydrocarbon group, preferably 2 to 12 (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) carbon atoms alkenyl group, more preferably 2 to The alkenyl group of 8 carbon atoms is more preferably the alkenyl group of 2 to 6 carbon atoms.
- Non-limiting examples include vinyl, propen-2-yl, buten-2-yl, buten-2-yl, penten-2-yl, penten-4-yl, hexen-2-yl, Hexen-3-yl, hepten-2-yl, hepten-3-yl, hepten-4-yl, octen-3-yl, nonen-3-yl, decen-4-yl and undecenyl En-3-yl.
- the alkenyl group may be further substituted with one or more substituents.
- Alkynyl refers to those containing 1 to 10 (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) carbon-carbon triple bonds, consisting of 2 to 20 carbon atoms Straight or branched chain unsaturated aliphatic hydrocarbon group, preferably 2 to 12 (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atom alkynyl group, more preferably 2 An alkynyl group having to 8 carbon atoms, and an alkynyl group having 2 to 6 carbon atoms is more preferable.
- Non-limiting examples include ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn-2-yl, butyn-3-yl, 3,3-dimethyl Butyn-2-yl, pentyn-1-yl, pentyn-2-yl, hexyn-1-yl, 1-heptyn-1-yl, heptyn-3-yl, heptyn-4- Base, octyn-3-yl, nonyn-3-yl, decyn-4-yl, undecyn-3-yl, dodecyn-4-yl.
- the alkynyl group may be optionally further substituted with one or more substituents.
- Aryl refers to a substituted or unsubstituted aromatic ring, which can be a 5- to 8-membered (e.g., 5, 6, 7, 8-membered) monocyclic ring, 5 to 12-membered (e.g., 5, 6, 7 , 8, 9, 10, 11, 12 membered) bicyclic or 10 to 15 membered (for example, 10, 11, 12, 13, 14, 15 membered) tricyclic ring system, which can be bridged or spiro ring, non-limiting implementation Examples include phenyl and naphthyl. The aryl group may be further substituted with one or more substituents.
- Heteroaryl refers to a substituted or unsubstituted aromatic ring, which can be 3 to 8 membered (e.g. 3, 4, 5, 6, 7, 8 membered) monocyclic, 5 to 12 membered (e.g. 5, 6, 7, 8, 9, 10, 11, 12 membered) bicyclic or 10 to 15 membered (e.g. 10, 11, 12, 13, 14, 15 membered) tricyclic ring system, and contains 1 to 6 (e.g. 1, 2, 3, 4, 5, 6) heteroatoms selected from N, O or S, preferably 5 to 8 membered heteroaryl groups, and 1 to 4 (e.g. 1, 2 , 3, 4) N and S can be oxidized into various oxidation states.
- 3 to 8 membered e.g. 3, 4, 5, 6, 7, 8 membered
- monocyclic e.g. 5, 6, 7, 8, 9, 10, 11, 12 membered
- 10 to 15 membered e.g. 10, 11, 12, 13, 14, 15 membered
- tricyclic ring system contains 1 to
- Heteroaryl groups can be attached to heteroatoms or carbon atoms. Heteroaryl groups can be bridged or spiro rings. Non-limiting examples include cyclopyridyl, furyl, thienyl, pyranyl, pyrrolyl, pyrimidinyl, Pyrazinyl, pyridazinyl, imidazolyl, piperidinyl benzimidazolyl, benzopyridyl, pyrrolopyridyl.
- the heteroaryl group is optionally further substituted with one or more substituents.
- Carbocyclic group or “carbocyclic ring” refers to a saturated or unsaturated aromatic ring or a non-aromatic ring.
- aromatic ring When it is an aromatic ring, its definition is the same as the definition of "aryl”above; when it is a non-aromatic ring, it can be 3 to 10 members (for example, 3, 4, 5, 6, 7, 8, 9, 10 Yuan), 4 to 12 yuan (e.g. 4, 5, 6, 7, 8, 9, 10, 11, 12 yuan) bicyclic ring or 10 to 15 yuan (e.g.
- tricyclic ring system which can be bridged or spiro ring
- non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-enyl, 1-cyclopentyl-2 -Alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl, cyclohexadienyl, cyclo Heptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl,
- the "carbocyclic group” or "carbocyclic ring” is optionally further substituted with one or more substituents.
- Heterocyclic group or “heterocyclic ring” refers to a saturated or unsaturated aromatic heterocyclic ring or non-aromatic heterocyclic ring. When it is an aromatic heterocyclic ring, its definition is the same as the definition of "heteroaryl” above; when When it is a non-aromatic heterocyclic ring, it can be a 3- to 10-membered (e.g. 3, 4, 5, 6, 7, 8, 9, 10-membered) monocyclic ring, 4 to 12-membered (e.g. 4, 5, 6, 7, 8, 9, 10, 11, 12 membered) bicyclic or 10 to 15 membered (e.g. 10, 11, 12, 13, 14, 15 membered) tricyclic ring system, and contains 1 to 4 (e.g.
- heteroatoms selected from N, O or S preferably 3 to 8 membered heterocyclic groups.
- One to four (for example, 1, 2, 3, 4) N and S optionally substituted in the "heterocyclic group” or “heterocyclic ring” can be oxidized to various oxidation states;
- heterocyclic group” or “Heterocycle” can be attached to a heteroatom or carbon atom;
- heterocyclic group” or “heterocycle” can be a bridged ring or a spiro ring.
- heterocyclic group or “heterocyclic ring” include oxirane, glycidyl, aziridinyl, oxetanyl, azetidinyl, thietanyl , 1,3-dioxolane, 1,4-dioxolane, 1,3-dioxanyl, azepanyl, oxepanyl, thiepanyl, oxygen Azepine, diazepine, thiazepine, pyridinyl, piperidinyl, homopiperidinyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyridine Azinyl, pyridazinyl, piperazinyl, homopiperazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazinyl, 1,3-
- Cycloalkyl refers to a saturated cyclic hydrocarbon group whose ring can be 3 to 10 membered (e.g. 3, 4, 5, 6, 7, 8, 9, 10 membered) monocyclic, 4 to 12 membered (e.g. 4, 5, 6, 7, 8, 9, 10, 11, 12 yuan) bicyclic or 10 to 20 yuan (e.g. 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 yuan)
- the ring carbon atoms preferably have 3 to 10 carbon atoms, and more preferably 3 to 8 carbon atoms.
- Non-limiting examples of "cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexyl Alkenyl, cycloheptenyl, 1,5-cyclooctadienyl, 1,4-cyclohexadienyl and cycloheptatrienyl, etc. When the cycloalkyl group is substituted, it may be further substituted with one or more substituents.
- Heterocycloalkyl refers to a substituted or unsubstituted saturated non-aromatic ring group, which can be 3 to 8 membered (for example, 3, 4, 5, 6, 7, 8 membered) monocyclic, 4 to 12 membered (E.g. 4, 5, 6, 7, 8, 9, 10, 11, 12-membered) bicyclic or 10 to 15-membered (e.g. 10, 11, 12, 13, 14, 15-membered) tricyclic ring system, including 1, 2 or 3 heteroatoms selected from N, O or S, preferably 3 to 8 membered heterocyclic group.
- the 1, 2, or 3 N and S optionally substituted in the "heterocycloalkyl” ring can be oxidized to various oxidation states; the "heterocycloalkyl” can be attached to a heteroatom or a carbon atom; “heterocycle “Alkyl” may be a bridged ring or a spiro ring.
- heterocycloalkyl include oxirane ethyl, aziridinyl, oxetanyl, azetidinyl, 1,3-dioxolane, 1,4-dioxolane, Oxolane, 1,3-dioxanyl, azepanyl, piperidinyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, tetrahydrofuranyl , Tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl, azabicyclo[3.2.1]octyl, azabicyclo[5.2.0]nonyl, oxa Tricyclic[5.3.1.1]dodecyl, azaadamantyl and oxaspiro[3.3]heptyl.
- “Pharmaceutically acceptable salt” or “pharmaceutically acceptable salt thereof” means that the compound of the present invention maintains the biological effectiveness and characteristics of the free acid or free base, and the free acid is combined with a non-toxic inorganic base or An organic base is a salt obtained by reacting the free base with a non-toxic inorganic acid or organic acid.
- “Pharmaceutical composition” refers to a mixture of one or more compounds of the present invention, their pharmaceutically acceptable salts or prodrugs, and other chemical components, where "other chemical components” refer to pharmaceutically acceptable compounds. Accepted carriers, excipients and/or one or more other therapeutic agents.
- Carrier refers to a material that does not cause significant irritation to the organism and does not eliminate the biological activity and characteristics of the administered compound.
- Excipient refers to an inert substance added to a pharmaceutical composition to facilitate the administration of a compound.
- Non-limiting examples include calcium carbonate, calcium phosphate, sugar, starch, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, granulating agents, lubricants, adhesives Agent and disintegrant.
- a “prodrug” refers to a compound of the present invention that can be converted into a biologically active compound by metabolism in the body.
- the prodrug of the present invention is prepared by modifying the amino or carboxyl group in the compound of the present invention, and this modification can be removed by conventional operations or in vivo to obtain the parent compound.
- the prodrug of the present invention is administered to a mammalian individual, the prodrug is split to form free amino or carboxyl groups.
- Co-crystal refers to the crystal formed by the combination of active pharmaceutical ingredient (API) and co-crystal former (CCF) under the action of hydrogen bonds or other non-covalent bonds.
- API active pharmaceutical ingredient
- CCF co-crystal former
- the pure state of API and CCF are both at room temperature. Solid, and there is a fixed stoichiometric ratio between the components.
- a eutectic is a multi-component crystal, which includes both a binary eutectic formed between two neutral solids and a multi-element eutectic formed between a neutral solid and a salt or solvate.
- Stepoisomers refer to isomers produced by the different arrangements of atoms in a molecule in space, including cis-trans isomers, enantiomers and conformational isomers.
- Optional or “optionally” or “selective” or “selectively” means that the event or condition described later can but does not necessarily occur, and the description includes the situation in which the event or condition occurs and its failures. What happened.
- heterocyclic group optionally substituted by an alkyl group means that the alkyl group may but does not necessarily exist, and the description includes the case where the heterocyclic group is substituted by an alkyl group and the case where the heterocyclic group is not substituted by an alkyl group.
- the structure of the compound is determined by nuclear magnetic resonance (NMR) or (and) mass spectrometry (MS).
- NMR shift ( ⁇ ) is given in units of 10 -6 (ppm).
- NMR is measured with (Bruker Avance III 400 and Bruker Avance 300) nuclear magnetic instrument, the solvent is deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD) ), the internal standard is tetramethylsilane (TMS);
- HPLC determination uses Agilent 1260DAD high pressure liquid chromatograph (Zorbax SB-C18 100 ⁇ 4.6mm, 3.5 ⁇ M);
- the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate.
- the size of the silica gel plate used for thin layer chromatography (TLC) is 0.15mm-0.20mm, and the size used for thin layer chromatography separation and purification products is 0.4mm. -0.5mm;
- the known starting materials of the present invention can be synthesized by or according to methods known in the art, or can be purchased from Titan Technology, Anaiji Chemical, Shanghai Demo, Chengdu Kelon Chemical, Shaoyuan Chemical Technology, Bailingwei Technology, etc. the company;
- Nitrogen atmosphere means that the reaction flask is connected to a nitrogen balloon with a volume of about 1L;
- the hydrogen atmosphere refers to the reaction flask connected to a hydrogen balloon with a volume of about 1L;
- the hydrogenation reaction is usually evacuated and filled with hydrogen, and the operation is repeated 3 times;
- the reaction temperature is room temperature, and the most suitable reaction temperature for room temperature is 20°C-30°C;
- THF Tetrahydrofuran
- PE petroleum ether
- NCS N-chlorosuccinimide
- Pd(dppf)Cl 2 [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride;
- DMSO dimethyl sulfoxide
- DNA Deoxyribonucleotides.
- IC 50 refers to a DNA-PK kinase activity by 50% inhibitory concentration of the compounds.
- 2,2,2-Trifluoroacetic anhydride (41 mL, 290.56 mmol) was added to a solution of compound 1c (38 g, 193.71 mmol) in tetrahydrofuran (400 mL) at 0°C. React at 80°C for 1h and concentrate. The obtained solid was slurried with a saturated sodium bicarbonate solution (100 mL ⁇ 3), filtered and dried to obtain the title compound 1d (red solid, 30 g, yield 100%).
- the seventh step is a first step.
- the compound 11a (120mg, 0.34mmol), cesium carbonate (220mg, 0.68mmol), [(2-di-cyclohexylphosphino-3,6-dimethoxy-2′,4′,6′-triiso Propyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl))palladium(II) methanesulfonate (30mg, 0.03mmol) was dissolved in Dioxane (5mL), protected by nitrogen and ventilated, stirred at 100°C for 4h.
- the compound 12a (100mg, 0.76mmol), compound 1j (250mg, 0.76mmol), cesium carbonate (500mg, 1.52mmol), [(2-di-cyclohexylphosphino-3,6-dimethoxy-2′ ,4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl))methanesulfonate palladium(II) methanesulfonic acid
- the ester (70mg, 0.08mmol) was dissolved in dioxane (10mL), protected with nitrogen and ventilated, and stirred at 100°C for 4h.
- the compound 14a (100mg, 0.76mmol), compound 1j (270mg, 0.8mmol), cesium carbonate (440mg, 1.34mmol), [(2-di-cyclohexylphosphino-3,6-dimethoxy-2' ,4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl))palladium(II) methanesulfonic acid
- the ester (61mg, 0.08mmol) was dissolved in dioxane (10mL), protected with nitrogen and ventilated, and stirred at 100°C for 4h.
- the compound 20a (200mg, 0.59mmol), compound 1e (88mg, 0.59mmol), cesium carbonate (586mg, 1.8mmol), methanesulfonic acid (2-dicyclohexylphosphine-3,6-dimethoxy-2' , 4',6'-triisopropyl-1,1'-biphenyl)) 2'-amino-1,1'-biphenyl-2-yl)palladium(II) (55mg, 0.059mmol) dissolved Put in dioxane (4mL), protect with nitrogen and ventilate, and stir at 100°C for 4h. The reaction was monitored by TLC until the reaction was complete. The reaction solution was concentrated.
- the compound 21a (200mg, 0.58mmol), compound 1e (86.3mg, 0.58mmol), cesium carbonate (567mg, 1.74mmol), methanesulfonic acid (2-dicyclohexylphosphine-3,6-dimethoxy-2 ',4',6'-triisopropyl-1,1'-biphenyl)) 2'-amino-1,1'-biphenyl-2-yl)palladium(II) (53mg, 0.058mmol) Dissolved in dioxane (4mL), protected by nitrogen and ventilated, and stirred at 100°C for 4h.
- the compound 20a (200mg, 0.58mmol), compound 22a (200mg, 1.19mmol), cesium carbonate (567mg, 1.74mmol), methanesulfonic acid (2-dicyclohexylphosphine-3,6-dimethoxy-2' , 4',6'-triisopropyl-1,1'-biphenyl)) 2'-amino-1,1'-biphenyl-2-yl)palladium(II) (53mg, 0.058mmol) dissolved Put in dioxane (4mL), protect with nitrogen and ventilate, and stir at 100°C for 4h.
- the seventh step is a first step.
- the compound 1e (300mg, 2.02mmol), compound 28g (850mg, 2.02mmol), cesium carbonate (1.3g, 4.04mmol), ((2-di-cyclohexylphosphino-3,6-dimethoxy-2 ′,4′,6′-Triisopropyl-1,1′-biphenyl)-2-(2′-amino-1,1′-biphenyl)) palladium(II) methanesulfonate
- the acid ester (183.12 mg, 0.2 mmol) was dissolved in dioxane (10 mL), protected with nitrogen and ventilated, and stirred at 100° C. for 4 h.
- Dissolve compound 34b (4.0g, 11.0mmol) in dichloromethane (40mL), add pyridine (3.48g. 44.0mmol) and trifluoroacetic anhydride (6.93g, 33.0mmol) in an ice bath, keep the temperature and continue the reaction for 1h, add Methanol (20mL), concentrate the crude product.
- the crude product was poured into a saturated NaHCO 3 solution (100 mL), a large amount of solid precipitated out, filtered and spin-dried to obtain compound 34c (light yellow solid, 3.3 g, yield 87.3%).
- the compound 34c (2.0g, 5.82mmol), compound 21a (1.96g, 11.64mmol), cesium carbonate (3.80g, 11.64mmol), [(2-di-cyclohexylphosphino-3,6-dimethoxy -2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-amino-1,1′-biphenyl))palladium(II) methanesulfonate
- the mesylate (528 mg, 0.582 mmol) was dissolved in dioxane (30 mL), protected with nitrogen and ventilated, and stirred at 100° C. for 4 h.
- the DNA-PK kinase assay kit (purchased from Promega, product number: V4107, batch number: 0000366495) was used to detect the inhibitory activity of the compound against DNA-PK kinase. Using chemiluminescence to quantify the results, the specific experimental plan is as follows:
- ii Prepare a 5 ⁇ L reaction system in a 384-well white plate, and add 1 ⁇ L of compound to each well (set concentration gradients of 1 ⁇ M, 200nM, 40nM, 8nM, 1.6nM, 0.32nM, 0.064nM, 0.013nM), 20units DNA- PK kinase, 0.2 ⁇ g/ ⁇ L substrate, 10 ⁇ g/ ⁇ L DNA, 50 ⁇ M ATP, 1% DMSO;
- control example is compound 3 of J. Med. Chem (2020), 63(7), 3461-3471, and the control example is prepared according to its preparation method.
- mice A549 cells (purchased from ATCC); Doxorubicin (Doxorubicin) liposome (Dox) (Lipo Doxorubicin, trade name "Libaoduo", purchased from Shanghai Fudan Zhangjiang Biomedical Co., Ltd.); 1, 6, 19, 22, 34; 6-week-old female nude mice (body weight 18-20g) (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.), 10 mice per group.
- Doxorubicin Doxorubicin liposome
- Dox Lipo Doxorubicin, trade name "Libaoduo", purchased from Shanghai Fudan Zhangjiang Biomedical Co., Ltd.
- 1, 6, 19, 22, 34 6-week-old female nude mice (body weight 18-20g) (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.), 10 mice per group.
- mice were adapted to the laboratory environment for 3 days. A549 cells were subcutaneously inoculated on the right ribs. The amount of inoculated cells was 5 ⁇ 10 6 per mouse. When the tumor grew to about 200 mm 3 , the efficacy experiment was carried out;
- mice that have successfully grown tumors, and set up a single Doxorubicin (Dox) group, a test compound and Dox combination group, and a control group (vehicle) for 21 days; mice are given intragastrically Medicine (ig), twice a day (BID, administration volume 5mL/kg; solvent: 5% DMSO+30% 2-hydroxypropyl- ⁇ -cyclodextrin).
- BID administration volume 5mL/kg
- solvent 5% DMSO+30% 2-hydroxypropyl- ⁇ -cyclodextrin
- Lipo Doxorubicin 2.5mg/kg was injected from the tail vein; once a week (QW, administration volume 5mL/kg;)
- QW administration volume 5mL/kg
- the specific dosing schedule is as follows:
Abstract
Description
化合物编号 | IC 50(nM) |
化合物1 | 1.30 |
化合物2 | 0.01 |
化合物3 | 14.95 |
化合物4 | 0.45 |
化合物5 | 3.87 |
化合物6 | 0.08 |
化合物7 | 0.01 |
化合物8 | 0.01 |
化合物9 | 1.10 |
化合物10 | 2.26 |
化合物11 | 0.10 |
化合物12 | 0.01 |
化合物13-1 | 0.68 |
化合物13-2 | 51.90 |
化合物14 | 0.01 |
化合物15 | 1.10 |
化合物16-1 | 0.52 |
化合物16-2 | 2.49 |
化合物17-1 | 0.01 |
化合物17-2 | 2.20 |
化合物18 | 0.06 |
化合物18-2 | 0.13 |
化合物19 | 0.03 |
化合物20-1 | 0.03 |
化合物20-2 | 1.10 |
化合物21-1 | 0.01 |
化合物21-2 | 0.10 |
化合物22 | 0.01 |
化合物23-1 | 2.84 |
化合物23-2 | 0.85 |
化合物24-1 | 0.66 |
化合物24-2 | 8.39 |
化合物25 | 0.01 |
化合物26 | 0.01 |
化合物27-1 | 10.5 |
化合物27-2 | 0.48 |
化合物28-1 | 0.75 |
化合物28-2 | 0.10 |
化合物29 | 0.50 |
化合物30 | 0.08 |
化合物31 | 0.10 |
化合物32 | 2.30 |
化合物33 | 6.40 |
化合物34 | 7.50 |
化合物35 | 0.48 |
化合物36 | 0.32 |
化合物37 | 1.30 |
对照例 | 100.20 |
Claims (10)
- 通式(I)所示的化合物,或者其立体异构体、溶剂化物、前药、代谢产物、氘代物、药学上可接受的盐或共晶:其中:A不存在或者选自4至12元的杂环,所述的杂环包含1至4个选自N、O或者S的杂原子;X 1、X 2各自独立选自C、O、N或者S,且当A选自4至12元的杂环时,X 1、X 2作为A环的一部分;B选自金刚烷基;R 0、R 1各自独立地选自H、卤素、羧基、=O、-OH、氰基、-NR a1R a2、C 1-6烷基、-C 1-6亚烷基-OH、-C 1-6亚烷基-NR a1R a2、C 1-6烷氧基、-C(=O)OC 1-6烷基、-C(=O)NR a1R a2、C 2-6烯基或者C 2-6炔基,所述的C 1-6烷基、C 1-6亚烷基和C 1-6烷氧基任选进一步被1-3个选自D或者卤素的取代基所取代;或者当n选自2、3或者4时,两个R 0与其相连的原子形成3至8元环,所述的3至8元环任选地包含1至3个选自N、O或者S的杂原子,所述的3至8元环任选进一步被1个或者多个选自-OH、羧基、卤素、氰基、=O、C 1-6烷基或者氨基的取代基所取代;R 2选自H或者C 1-6烷基;R 3选自H、卤素、C 1-6烷基或者C 1-6烷氧基;R 4选自H、C 1-6烷基、C 3-12环烷基、C 3杂环烷基或者C 4-12杂环烷基,所述的C 3杂环烷基或者C 4-12杂环烷基包含1至3个选自N、O或者S的杂原子,所述的C 1-6烷基、C 3-12环烷基、C 3杂环烷基或者C 4-12杂环烷基任选被1个或者多个选自-OH、D、卤素、氰基、羧基、-NH 2、=O、-C(=O)NH 2、C 1-6烷基、-C 1-6亚烷基-OH、C 1-6烷氧基、C 2-6烯基、C 2-6炔基、C 3-12环烷基、C 3杂环烷基、C 4-12杂环烷基、C 6-12芳基或者C 5-12杂芳基的取代基所取代;或者,R 3和R 4与其相连的原子形成4至12元杂环,所述的杂环包含1至3个选自N、O或者S的杂原子,所述的4至12元杂环任选被1个或者多个选自-OH、羧基、卤素、氰基、=O、C 1-6烷基、C 1-6杂烷基、C 2-6烯基、C 2-6炔基、-NR a1R a2、-C(=O)OC 1-6烷基、-C(=O)NR a1R a2、C 3-12环烷基、C 3杂环烷基、C 4-12杂环烷基、C 6-12芳基或者C 5-12杂芳基的取代基所取代;且所述的C 1-6烷基、C 1-6杂烷基、C 2-6烯基或者C 2-6炔基任选进一步被1个或者多个选自-OH、羧基、氰基、卤素、-O-R a1、-NR a1R a2、C 3-12环烷基、C 3杂环烷基、C 4-12杂环烷基、C 6-12芳基或者C 5-12杂芳基的取代基所取代;R 5选自-OH、卤素、D、氰基、羧基、=O、C 1-6烷基、C 1-6烷氧基、C 2-6烯基、C 2-6炔基、-NR a1R a2、-C(=O)OC 1-6烷基、-OC(=O)C 1-6烷基、-C(=O)NR a1R a2、C 3-12环烷基、C 3杂环烷基、C 4-12杂环烷基、C 6-12芳基或者C 5-12杂芳基,且所述C 1-6烷基、C 1-6烷氧基、C 3-12环烷基、C 4-12杂环烷基、C 6-12芳基、C 5-12杂芳基任选进一步被1至3个选自OH、羧基、卤素、C 1-6烷基、C 1-6烷氧基、-NR a1R a2或者=O的取代基所取代;R a1、R a2各自独立地选自H、C 1-6烷基、-C(=O)R a3或者-C(=O)NR a4R a5,其中所述的C 1-6烷基任选进一步被1个或者多个选自OH、卤素、C 1-6烷基、C 1-6烷氧基、C 6-12芳基、C 5-12杂芳基、C 3-12环烷基、C 3杂环烷基或者C 4-12杂环烷基的取代基所取代;或 者R a1与R a2及N原子形成3至12元杂环,所述的3至12元杂环含有1个至4个选自N、O或者S的杂原子;R a3选自C 1-6烷基、C 1-6烷氧基或者C 6-12芳基;R a4、R a5各自独立地选自H或者C 1-6烷基;或者R a4与R a5及N原子形成3至12元杂环,所述的3至12元杂环包含1个至4个选自N、O或者S的杂原子;W选自O或者S;n、p、q各自独立地为0、1、2、3或者4;
- 根据权利要求1所述的化合物,或者其立体异构体、溶剂化物、代谢产物、前药、氘代物、药学上可接受的盐或共晶,其中该化合物为通式(II)所示的化合物:其中:A不存在或者选自4至12元的杂环,所述的杂环包含1至4个选自N、O或者S的杂原子;X 1、X 2各自独立选自C或者N,且当A选自4至12元的杂环时,X 1、X 2作为A环的一部分;B选自金刚烷基;R 0、R 1各自独立地选自H、卤素、羧基、=O、-OH、氰基、-NR a1R a2、C 1-6烷基、-C 1-6亚烷基-OH、-C 1-6亚烷基-NR a1R a2、C 1-6烷氧基、-C(=O)OC 1-6烷基、-C(=O)NR a1R a2、C 2-6烯基或者C 2-6炔基;所述的C 1-6烷基、C 1-6亚烷基和C 1-6烷氧基任选进一步被1-3个选自D或者卤素的取代基所取代;或者当n选自2、3或者4时,两个R 0与其相连的原子可以形成3至8元环,所述的3至8元环任选地包含1至3个选自N、O或者S的杂原子,所述的3至8元环任选进一步被1个或者多个选自-OH、羧基、卤素、氰基、=O、C 1-6烷基或者氨基的取代基所取代;R 3选自H、卤素、C 1-6烷基或者C 1-6烷氧基;R 4选自H、C 1-6烷基、C 3-12环烷基、C 3杂环烷基或者C 4-12杂环烷基,所述的C 3杂环烷基或者C 4-12杂环烷基包含1至3个选自N、O或者S的杂原子,所述的C 1-6烷基、C 3-12环烷基、C 3杂环烷基或者C 4-12杂环烷基任选被1个或者多个选自-OH、D、卤素、氰基、羧基、-NH 2、=O、-C(=O)NH 2、C 1-6烷基、-C 1-6亚烷基-OH、C 1-6烷氧基、C 2-6烯基、C 2-6炔基、C 3-12环烷基、C 3杂环烷基、C 4-12杂环烷基、C 6-12芳基或者C 5-12杂芳基的取代基所取代;R 5选自-OH、D、卤素、氰基、羧基、=O、C 1-6烷基、C 1-6烷氧基、C 2-6烯基、C 2-6炔基、-NR a1R a2、-C(=O)OC 1-6烷基、-OC(=O)C 1-6烷基、-C(=O)NR a1R a2、C 3-12环烷基、C 3杂环烷基、C 4-12杂环烷基、C 6-12芳基或者C 5-12杂芳基,且所述C 1-6烷基、C 1-6烷氧基、C 3-12环烷基、C 4-12杂环烷基、C 6-12芳基、C 5-12杂芳基任选进一步被1至3个选自OH、羧基、卤素、C 1-6烷基、C 1-6烷氧基、-NR a1R a2或者=O的取代基所取代;R a1、R a2各自独立地选自H、C 1-6烷基、-C(=O)R a3或者-C(=O)NR a4R a5,其中所述的C 1-6烷基任选进一步被1个或者多个选自OH、卤素、C 1-6烷基、C 1-6烷氧基、C 6-12芳基、C 5-12杂芳基、C 3-12环烷基、C 3杂环烷基或者C 4-12杂环烷基的取代基所取代;或 者R a1与R a2及N原子形成3至12元杂环,所述的3至12元杂环包含1个至4个选自N、O或者S的杂原子;R a3选自C 1-6烷基、C 1-6烷氧基或者C 6-12芳基;R a4、R a5各自独立地选自H或者C 1-6烷基;或者R a4与R a5及N原子形成3至12元杂环,所述的3至12元杂环包含1个至4个选自N、O或者S的杂原子;n、p、q各自独立地为0、1、2、3或者4;
- 根据权利要求3所述的化合物,或者其立体异构体、溶剂化物、代谢产物、前药、氘代物、药学上可接受的盐或共晶,其中:A不存在或者选自5元的杂环,所述的5元的杂环包含1至3个选自N或者O的杂原子;X 1、X 2各自独立选自C或者N,且当A选自5元的杂环时,X 1、X 2作为A环的一部分;B选自金刚烷基;R 0选自H;R 1选自H、卤素、C 1-4烷基、氰基或者-C(=O)NR a1R a2;所述的C 1-4烷基任选进一步被1-3个选自D或者卤素的取代基所取代;R 3选自H;R 4选自H或者C 1-4烷基;R 5选自-OH、D、氰基、-NR a1R a2、C 1-4烷基、C 1-4烷氧基、-C(=O)OC 1-4烷基、羧基、卤素、=O或者-C(=O)NR a1R a2,且所述C 1-4烷基、C 1-4烷氧基任选进一步被1至3个选自OH或者卤素的取代基所取代;R a1、R a2各自独立地选自H或者C 1-4烷基;或者R a1与R a2及N原子形成6元杂环,所述的6元杂环包含1个至2个选自N或者O的杂原子;n选自0或者1;p选自1、2或者3;q选自1或者2;
- 药物组合物,所述药物组合物包括:(1)权利要求1至4中任一项所述的化合物或其立体异构体、溶剂化物、代谢产物、氘代物、药学上可接受的盐、共晶或者前药;(2)任选的一种或者多种其他活性成分;以及(3)药学上可接受的载体和/或赋形剂。
- 权利要求1-5任一项所述的化合物或其立体异构体、溶剂化物、代谢产物、氘代物、药学上可接受的盐、共晶或者前药或者权利要求8所述的药物组合物在制备DNA-PK抑制剂中的用途。
- 权利要求1-5任一项所述的化合物或其立体异构体、溶剂化物、代谢产物、氘代物、药学上可接受的盐、共晶或者前药或者权利要求8所述的药物组合物在制备用于治疗与预防癌症的药物中的用途。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227021886A KR20220107026A (ko) | 2019-12-31 | 2020-12-30 | 퓨린 유도체 및 의학에서의 그의 용도 |
JP2022539656A JP7428806B2 (ja) | 2019-12-31 | 2020-12-30 | プリン誘導体および医薬におけるその使用 |
EP20909351.7A EP4086258A4 (en) | 2019-12-31 | 2020-12-30 | PURINE DERIVATIVE AND MEDICAL USE THEREOF |
US17/758,155 US20220402920A1 (en) | 2019-12-31 | 2020-12-30 | Purine derivative and medical use thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911408681 | 2019-12-31 | ||
CN201911408681.4 | 2019-12-31 | ||
CN202010155797 | 2020-03-11 | ||
CN202010155797.8 | 2020-03-11 | ||
CN202010667388.6 | 2020-07-15 | ||
CN202010667388 | 2020-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021136463A1 true WO2021136463A1 (zh) | 2021-07-08 |
Family
ID=76685864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/141862 WO2021136463A1 (zh) | 2019-12-31 | 2020-12-30 | 嘌呤衍生物及其在医药上的用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220402920A1 (zh) |
EP (1) | EP4086258A4 (zh) |
JP (1) | JP7428806B2 (zh) |
KR (1) | KR20220107026A (zh) |
CN (1) | CN113121574B (zh) |
WO (1) | WO2021136463A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022135360A1 (zh) * | 2020-12-21 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
WO2022199547A1 (zh) * | 2021-03-22 | 2022-09-29 | 成都赜灵生物医药科技有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
WO2023274310A1 (zh) * | 2021-06-29 | 2023-01-05 | 成都百裕制药股份有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
CN116239610A (zh) * | 2023-02-23 | 2023-06-09 | 遵义医科大学珠海校区 | 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116406272A (zh) * | 2020-07-20 | 2023-07-07 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
WO2023025160A1 (zh) * | 2021-08-23 | 2023-03-02 | 成都百裕制药股份有限公司 | 一种咪唑啉酮衍生物的制备工艺及其中间体 |
CN117412969A (zh) * | 2021-09-23 | 2024-01-16 | 成都百裕制药股份有限公司 | 咪唑啉酮衍生物的晶型 |
CN114773333A (zh) * | 2021-12-25 | 2022-07-22 | 上海泰坦科技股份有限公司 | 一种卤代三唑并吡啶的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006091737A1 (en) * | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
CN110177791A (zh) * | 2016-12-20 | 2019-08-27 | 阿斯利康(瑞典)有限公司 | 氨基-三唑并吡啶化合物及其在治疗癌症中的用途 |
WO2019238929A1 (en) * | 2018-06-15 | 2019-12-19 | Astrazeneca Ab | Purinone compounds and their use in treating cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106986863B (zh) * | 2012-04-24 | 2019-12-31 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
RS57306B1 (sr) * | 2013-10-17 | 2018-08-31 | Vertex Pharma | Inhibitori dnk-pk |
JP2019504069A (ja) * | 2016-01-22 | 2019-02-14 | スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド | 窒素含有複素環アミド誘導体及びその製造方法、並びに医薬上の用途 |
WO2019015593A1 (zh) | 2017-07-19 | 2019-01-24 | 江苏奥赛康药业股份有限公司 | 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 |
-
2020
- 2020-12-30 JP JP2022539656A patent/JP7428806B2/ja active Active
- 2020-12-30 KR KR1020227021886A patent/KR20220107026A/ko not_active Application Discontinuation
- 2020-12-30 EP EP20909351.7A patent/EP4086258A4/en active Pending
- 2020-12-30 CN CN202011616026.0A patent/CN113121574B/zh active Active
- 2020-12-30 US US17/758,155 patent/US20220402920A1/en active Pending
- 2020-12-30 WO PCT/CN2020/141862 patent/WO2021136463A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006091737A1 (en) * | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
CN110177791A (zh) * | 2016-12-20 | 2019-08-27 | 阿斯利康(瑞典)有限公司 | 氨基-三唑并吡啶化合物及其在治疗癌症中的用途 |
WO2019238929A1 (en) * | 2018-06-15 | 2019-12-19 | Astrazeneca Ab | Purinone compounds and their use in treating cancer |
Non-Patent Citations (3)
Title |
---|
GOLDBERG FREDERICK W., FINLAY M. RAYMOND V., TING ATTILLA K. T., BEATTIE DAVID, LAMONT GILLIAN M., FALLAN CHARLENE, WRIGLEY GAIL L: "The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5- a ]pyridin-6-yl)amino]-9-(tetrahydro-2 H -pyran-4-yl)-7,9-dihydro-8 H -purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 63, no. 7, 9 April 2020 (2020-04-09), pages 3461 - 3471, XP055826430, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01684 * |
J. MED. CHEM, vol. 63, no. 7, 2020, pages 3461 - 3471 |
See also references of EP4086258A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022135360A1 (zh) * | 2020-12-21 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
WO2022199547A1 (zh) * | 2021-03-22 | 2022-09-29 | 成都赜灵生物医药科技有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
WO2023274310A1 (zh) * | 2021-06-29 | 2023-01-05 | 成都百裕制药股份有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
CN116239610A (zh) * | 2023-02-23 | 2023-06-09 | 遵义医科大学珠海校区 | 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用 |
CN116239610B (zh) * | 2023-02-23 | 2024-01-16 | 遵义医科大学珠海校区 | 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113121574B (zh) | 2023-02-17 |
JP7428806B2 (ja) | 2024-02-06 |
EP4086258A4 (en) | 2023-11-29 |
EP4086258A1 (en) | 2022-11-09 |
CN113121574A (zh) | 2021-07-16 |
US20220402920A1 (en) | 2022-12-22 |
JP2023509011A (ja) | 2023-03-06 |
KR20220107026A (ko) | 2022-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021136463A1 (zh) | 嘌呤衍生物及其在医药上的用途 | |
WO2021121367A1 (en) | Kras mutant protein inhibitors | |
EP3555070B1 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
JP6782255B2 (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
CN112955459A (zh) | 双环肽配体和其用途 | |
FR2928645A1 (fr) | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation | |
EA023350B1 (ru) | Противомикробные соединения, способы их получения и применение | |
US11634407B2 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
CA2938187C (en) | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | |
JP6333996B2 (ja) | がんを予防または治療するための、ブロモドメイン阻害化合物およびそれを含む医薬組成物 | |
WO2021136461A1 (zh) | 嘌呤衍生物及其在医药上的应用 | |
US9724331B2 (en) | Use of maleimide derivatives for preventing and treating leukemia | |
KR20230027214A (ko) | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 | |
WO2018054304A1 (zh) | 呋喃并喹啉二酮类化合物及其医药用途 | |
EP3542796A1 (en) | Compound having anti-cancer effect, and preparation method therefor and use thereof | |
WO2022143533A1 (zh) | 喹唑啉衍生物及其在医药上的应用 | |
US11351151B2 (en) | Compound having anticancer activity and preparation method and application | |
LU505117B1 (en) | A pan-KRAS inhibitor compound | |
BR112014026776B1 (pt) | Derivados de pirimidina, seu uso no tratamento de doenças bacterianas, composição e combinação farmacêuticas e produto de preparação combinada | |
WO2022272074A1 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
EP4284514A1 (en) | Heteroaromatic phosphonium salts and their use treating cancer | |
WO2022214008A1 (zh) | 高活性hpk1激酶抑制剂 | |
WO2022152313A1 (zh) | 嘧啶衍生物及其在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20909351 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20227021886 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022539656 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020909351 Country of ref document: EP Effective date: 20220801 |